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Purpose: The aim of the present study was to characterise gliclazide solid dispersions (SDs) prepared 
with polyethylene glycol (PEG) 8000 and compare them with SDs in PEG 6000.  
Methods: Gliclazide SDs containing varying concentrations of PEG 8000 were prepared using the 
fusion – solvent technique, and their phase solubility behavior and dissolution in 0.1N HCl were 
assessed at 37 oC. The physical state of, and gliclazide-PEG interactions in, SDs and physical mixtures 
prepared in ratios of 1:1, 1:2 and 1:5 (gliclazide: PEG 8000), respectively, were characterized by x-ray 
diffraction (XRD), Fourier-transform infrared (FTIR) spectroscopy and differential scanning calorimetry 
(DSC).   
Results: The solubility of gliclazide increased with increasing amount of PEG 8000 in aqueous medium. 
Gibbs free energy (∆Gotr) values were all negative, indicating the spontaneous nature of gliclazide 
solubilisation. Dissolution studies indicated a significant increase in the dissolution of gliclazide when 
dispersed in PEG 8000. FTIR analysis demonstrated the absence of well-defined gliclazide - PEG 8000 
chemical interaction while DSC and XRD studies indicated the amorphous /microcrystalline state of 
gliclazide in the SDs.  
Conclusion: In both solid dispersions and physical mixture, PEG 8000 increases the solubility and 
dissolution rate of gliclazide. The increased dissolution rate of gliclazide may be due to the formation of 
microcrystals, increased wettability and dispersibility in systems containing PEG 8000.  
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INTRODUCTION 
 
Gliclazide is a second generation 
hypoglycemic sulfonylurea which is useful 
in the treatment of type 2 diabetes mellitus 
[1].
 
Current literature shows that the drug 
has good tolerability, low incidence of 
hypoglycemia, low rate of secondary failure, 
inhibits platelet aggregation and increases 
fibrinolysis [2,3].
  
For these reasons, glicla-
zide appears to be a drug of choice in long-
term sulfonylurea therapy for the control of 
type 2 diabetes mellitus in the aged [4]. 
Gliclazide exhibits inter-individual bioavaila-
bility variations probably due to its poor 
aqueous solubility and unsatisfactory 
dissolution rate. Improvement in its 
solubility and dissolution rate is the primary 
reason for this study, as this improvement 
could be achieved by the use of water-
soluble polymers based on solid dispersion 
technology [5].  
 
Complexation of gliclazide with β-cyclodextrin 
and the characterization of the resulting 
complex has been reported [6,7,8]. 
Complexation of gliclazide with β-
cyclodextrin-hydroxypropyl methylcellulose 
enhanced its hypoglycemic activity has been 
reported [9]. In addition, accelerated 
absorption of gliclazide using PEG 400 was 
studied earlier [10]. These studies showed 
enhancement in gliclazide dissolution. The 
solid dispersions (SDs) of drugs with PEG 
8000 may be useful to solve various 
problems such as enhancement of stability,
 
solubility and dissolution rate [11,12].   
 
Our previous study on solid dispersions of 
gliclazide prepared with PEG 6000 indicated 
improvement in the dissolution rate of this 
poorly water soluble drug. The gliclazide: 
PEG 6000 (1:5) solid dispersion, which is 
partially amorphous, showed approximately 
90 % drug release within one hour compared 
with 40% for the pure drug[13]. Since the 
molecular weight of PEG may play a role in 
the performance of a solid dispersion, the 
objective of the present work was to 
investigate the effect of the higher molecular 
weight PEG 8000 on the dissolution rate of 
gliclazide-PEG 8000 solid dispersion. The 
interactions between gliclazide and PEG 
8000 in both solid and solution states were 
investigated. The interaction in the solid state 
was investigated by Fourier-transform 
infrared (FT-IR) spectroscopy, X-ray 
diffraction (XRD) and differential scanning 
calorimetry (DSC) while interaction  in 
solution  was  studied  by  phase  solubility  






Gliclazide was received as gift from Aristo 
Pharmaceuticals Ltd, Mumbai, India. PEG 
8000 was received from Clariant, Germany. 
Double distilled water was used throughout 
the study and all the other chemicals used 
were of analytical grade.  
 
Preparation of solid dispersions 
 
The SDs were prepared at weight ratios of 
1:1, 1:2, 1:5 (gliclazide: PEG 8000) and 
coded SD1/1, SD1/2 and SD 1/5 
respectively, using the fusion-solvent 
method.  The required amount of PEG 8000 
was melted in a beaker on a water bath 
maintained at 50–65 
o
C. The appropriate 
amount of gliclazide solution in chloroform 
(16.6 %w/v) was added to the molten PEG 
8000 and mixed thoroughly with a glass rod 
for 5 min. The mixture was cooled rapidly 
by placing the beaker in an ice bath for 5 
min to solidify, then powdered in a mortar, 
sieved through a 100-mesh screen, and 
stored in a screw-cap vial at room 
temperature pending further use. 
 
The physical mixtures (PMs) in the same 
weight ratio as the SDs above were 
prepared by thoroughly mixing the 
appropriate amounts of gliclazide and PEG 
8000 for 10 min in a mortar. The mixtures, 
coded PM 1/1, PM 1/2 and PM 1/5, 
respectively were sieved through a 100-
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mesh sieve and stored in screw-cap vials at 
room temperature until used. 
 
Determination of gliclazide solubility 
 
Solubility determinations were performed in 
triplicate according to the method of Higuchi 
and Connors [14]. In brief, an excess 
amount of gliclazide was taken into a 
screw-capped glass vial to which 20 mL of 
aqueous solution containing various 
concentrations (2-18 %) of PEG 8000 was 
added. The samples were shaken at 
37.0±0.5 
o
C for 72 h in a water bath (Remi 
Pvt Ltd, Mumbai) and filtered through a 
0.45µm membrane filter. The filtrate was 
suitably diluted and analyzed 
spectrophotometrically at the wavelength of 
227 nm using a UV-VIS spectrophotometer 




Dissolution studies on gliclazide powder as 
well as the SDs, and PMs were performed 
using the U.S. Pharmacopoeia (USP) tablet 
dissolution test apparatus 2 (Lab India, 
Mumbai.) with the paddle rotating at 50 rpm 
in 900 mL 0.1N HCl (containing 0.25 %w/v 
sodium lauryl sulphate) at 37±0.5 
o
C. SDs 
or PMs equivalent to 30 mg of gliclazide 
were used as samples for the dissolution 
test. At 10 min intervals, 10 mL samples 
were withdrawn with a syringe filter 
(0.45µm) (Sepyrane, Mumbai) and assayed 
for gliclazide content by measuring the 
absorbance at 227 nm using UV-Visible 
spectrophotometer (Shimadzu UV-1700, 
PharmSpec). Fresh medium (10 mL), 
prewarmed at 37
o
C, was added to the 
dissolution medium after each sampling to 
maintain a constant volume throughout the 
test. Dissolution studies were performed in 
triplicate (n=3).  
 
Fourier-transform infrared (FTIR) 
spectroscopy 
 
Fourier-transform infrared (FT-IR) spectra 
were obtained using an FT-IR 
spectrometer-430 (Jasco, Japan). The 
samples (gliclazide, SDs or PMs) were 
previously ground and mixed thoroughly 
with potassium bromide, an infrared 
transparent matrix, at 1:5 (Sample: KBr) 
ratio, respectively. The KBr discs were 
prepared by compressing the powders at a 
pressure of 5 tons for 5 min in a hydraulic 
press. Forty scans were obtained at a 
resolution of 4 cm
-1




Differential scanning calorimetry 
 
DSC measurements were performed on a 
DSC-6100 (Seiko Instruments, Japan) 
differential scanning calorimeter with a 
thermal analyzer. Samples (about 1.675 mg 
of gliclazide or SDs and PMs containing an 
equivalent amount of the drug) were placed 
in sealed aluminum pans and heated under 





 from 25 to 250 
o
C.  An empty 




X-ray powder diffraction patterns were 
obtained at room temperature using a 
PW1710 X-ray diffractometer (Philips, 
Holland) with Cu as anode material and 
graphite monochromator, operated at a 
voltage of 35 kV and 20 mA current. The 
samples were analysed in the 2θ angle 
range of 5˚–70˚ and the process 
parameters were set as: scan step size of 
0.02˚ (2θ), and scan step time of 0.5s. 
 
Solubility and dissolution data analysis 
Phase-solubility  
 
The value of apparent stability constant, Ks, 
between drug–carrier combinations were 
computed from the phase-solubility profiles, 
as shown in Eqn 1. 
                                       
)Slope-1(Intercept
Slope
=Ks      …..  (1) 
 
Gibbs free energy of transfer (∆Gtr
o
) of 
gliclazide from pure water to the aqueous 
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solutions of carrier was calculated as in Eqn 
2: 
           Τ=∆
Ss
So
LogRtr 303.2-G …….. 
 
(2) 
where So/Ss is the ratio of molar solubility of 
gliclazide in aqueous solution of PEG 8000 
to that of the same medium without PEG 
8000. 
 
In vitro dissolution 
 
A model-independent approach was used for 
comparing the dissolution profiles. Model-
independent approaches are based on the 
ratio of area under the dissolution curve 
(dissolution efficiency) or on mean dissolution 
time
15,16
.  The magnitude of mean dissolution 
time and dissolution efficiency for each 
formulation was calculated using PCP Disso 
v3 software (Pune, India) based on Eqn 3. 








       …………  (3) 




The phase-solubility diagram investigated in 
0.1N HCl (pH 1.2) was linear over a wide 
range of PEG 8000 concentrations and 
correspond to AL-type profiles [14]. The 
stability constant was 0.328 mL
-1
mg. At 18 
%w/v concentration of PEG 8000, the 
solubility of gliclazide increased by 4.46-fold 
(Table 1). Table 1 also presents the values of 
Gibbs free energy associated with the 
aqueous solubility of gliclazide in the 




Q10, Q20 and Q30 values (percent drug 
dissolved within 30 min) are reported in Table 
2. From Table 2, it is evident that the onset of 
dissolution of pure gliclazide was very slow 
(40.82% of drug was dissolved within 30 
min). The dissolution rate of gliclazide SDs 
was considerably enhanced by PEG 8000 
within 30 min compared to pure gliclazide 
and PMs. DE10min were: pure gliclazide 
(9.16%), PMs (23.72%) and SDs (41.4%). 
DE30min increased subsequently to as high as 
47.35 % for PMs and 74.23 % for SDs (see 
Table 2). 
 
Mean dissolution times (MDT) for pure 
gliclazide, PMs and SDs are also presented 
in Table 2. MDT of pure gliclazide was 12.5 
min but decreased to 8 min for SDs at 1:5 
(gliclazide: PEG 8000) ratio.  
 
Table 1: Effect of PEG 8000 concentration and 
Gibbs free energy on the solubility of gliclazide 
 
Concentration 








0 0.81 ± 0.02 - 
2 0.86 ± 0.01 -150 
4 1.23 ± 0.05 -1079 
6 1.53 ± 0.01 -1643 
8 1.85 ± 0.05 -2124 
10 2.21 ± 0.08 -2588 
12 2.58± 0.09 -2990 
14 2.96 ± 0.01 -3344 
16 3.32 ± 0.02 -3636 




Fourier-transform infrared (FT-IR) spectro-
scopy was used to characterize possible 
interactions between the drug and the 
carrier in solid state. The IR spectra of SDs 
and PMs are compared with the standard 
spectrum of gliclazide in Fig 1A. The IR 
spectrum of gliclazide was characterized by 
the absorption of carbonyl (C=O) sulphonyl 






   
respectively
6
. In the spectra of 
SDs and PMs, the carbonyl (C=O) 
sulphonyl urea group was shifted towards 
higher frequencies at 1711 cm
-1
 and 1716 
cm
-1
, respectively but the NH group band 
peak disappeared in SDs. The sulphonyl 





 in pure gliclazide. In SDs, the 
asymmetrical vibration peak of S=0 band 
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was shifted from 1349 cm
-1
 to 1343  cm
-1
 
with decreased frequencies. In SDs, the 
symmetrically stretching vibration band of 
S=0 was shifted from 1162 cm
-1
  to 1100 
cm
-1
  with decreased frequencies. Important 
vibrations detected in the spectrum of PEG 
8000 were the C-H stretching at 2895 cm
-1  






Figure 1: FTIR spectra of gliclazide alone (A), 
PEG 8000 alone (B), gliclazide-PEG 8000 PMs 
(C), and gliclazide-PEG 8000 SDs (D). 
 
X-ray diffractions (XRD) 
 
The diffraction spectrum of pure gliclazide 
showed that the drug was crystalline in 
nature as demonstrated by numerous 
peaks. Numerous diffraction peaks of 
gliclazide were observed at 20 of 10.59, 
14.98, 17.2, 17.85, 18.15, 22.07, 25.42, 
26.25, 26.75 and 29.5 (Fig 2 A) indicating 
crystalline gliclazide. Pure PEG 8000 
showed two peaks with the highest intensity 
at 2θ and d-spacings of 19.10 and 4.64 A˚, 
22.89 and 3.88 A˚ 23.18 and 3.83 A˚ and 
23.43 and 3.79 A˚. Some changes in the 
peak positions of gliclazide were observed 
in PMs as well as SDs. The prominent 
peaks for pure gliclazide were clearly seen 
at the same positions in PMs and SDs but 
with decreased intensities such as at 2θ of 
10.59 (from 1138 to 1910 counts in PMs 
and down to 562 counts in SDs), 14.98 
(from 558 to 269 counts in PMs and to 139 
counts in SDs), 17.1 (from 682 to 256 
counts  in PMs and to 104 counts in SDs), 
18.15 (from 1068 to 475 counts  in PMs and 
to 266 counts in SDs), etc .  
 
Table 2: In vitro dissolution of gliclazide, as well as its physical mixtures and solid dispersions of 





















Drug 18.46 32.67 40.82 9.16 23.67 12.5 
PM 1
1  27.2 43.2 59.1 13.62 33.32 16.2 
PM 2
1  30.9 47.8 62.6 15.45 36.67 15.9 
PM 5
1  47.44 61.62 65.96 23.72 47.35 12.0 
SD 1
1  78.25 82.54 85.34 39.13 67.82 7.6 
SD 2










1  82.8 91.7 96.5 
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Figure 2: X-ray diffractograms of gliclazide alone 
(A), PEG 8000 alone (B), gliclazide-PEG 8000 PM 
(C), and gliclazide-PEG 8000 SD (D).  
 
Differential scanning calorimetry  
 
The DSC curve of pure gliclazide exhibited a 
single endothermic response corresponding 
to the melting of the drug. Onset of melting 
was observed at 170.8 ˚C and the 
corresponding heat of fusion (∆HF) was 171.8 
J/g (Fig 3A) while pure PEG 8000 showed a 
melting endotherm at 60.8 ˚C with a ∆HF of 
254.5 J/g. Thermograms of SDs (Fig 3D) 
showed absence of a gliclazide melting peak 
but one exothermic peak was present at 




Figure 3: DSC thermograms of gliclazide alone 
(A), PEG 8000 alone (B), gliclazide-PEG 8000 PM 






The phase-solubility results are in 
accordance with the well established 
formation of soluble complexes between 
water soluble polymeric carriers and poorly 
water soluble drugs
17
. Increased solubility 
may be due to improved dissolution of 
gliclazide particles in aqueous solution by 
PEG 8000. An indication of the process of 
transfer of gliclazide from pure water to the 
aqueous solution of PEG 8000 may be 
obtained from the values of Gibbs free 
energy change. ∆Gtr
o 
values were all negative 
for PEG 8000 at various concentrations 





The increase in the dissolution kinetics of 
gliclazide from polyethylene glycol SDs might 
be due to the reduction of crystal size, 
absence of aggregation of drug crystals and 




ment in the wettability of the gliclazide might 
have resulted from the formation of a film of 
polyethylene glycol around it, thus reducing 
the hydrophobicity of their surfaces. This 









The shift of the peaks of gliclazide in SDs 
was as a result of physical interaction 
between gliclazide and PEG 8000. However, 
the disappearance of NH peak of gliclazide in 
SDs could be due to hydrogen bonding 
between the hydrogen atom of the NH group 
of gliclazide and one of the ion pairs of 
oxygen atom in the PEG 8000.  
 
X-ray diffraction  
 
The relative reduction of diffraction intensity 
of gliclazide in SD preparations at these 
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angles suggests that the size of the crystals 
was reduced to that of microcrystals
19
. The 
positions of PEG 8000 peak patterns in the 
PMs and SDs were the same and 
superimposable, which again rules out the 
possibility of well defined chemical 
interaction and new compound formation 
between these two components. The 
results of this study imply that gliclazide is 
present in partially crystalline or 
microcrystalline form in the SDs. Valizaden 
et al characterized indomethacin-PEG 6000 
SDs prepared by a fusion method and 
concluded that the drug was in 
microcrystalline form and that no chemically 
well-defined interaction took place between 
indomethacin and PEG 6000 either in 
solution or in the solid state
20
. The present 
finding, i.e., the presence of microcrystal or 
a partially crystalline state of gliclazide in 
SDs is in agreement with results for other 
drugs
20
.      
 
Differential scanning calorimetry  
 
The absence of a gliclazide melting peak 
and the presence of one exothermic peak in 
SD suggest that gliclazide was completely 
soluble in the liquid phase of the polymer or 
the absence of a crystalline form of 
gliclazide. The exothermic peak might be 
due to crystallisation above Tg (glass 
transition temperature). The molecular 
motion of amorphous solids depends on 
temperature. The kinetic energy of 
amorphous solids increases significantly as 
the temperature gets close to Tg. Due to 
the thermodynamic instability of amorphous 
solids, compared to the crystalline state, 
spontaneous crystallisation is always 
possible as soon as molecular mobility is 
above the threshold of nucleation.   
However, the melting peak of PEG 8000 in 
SDs was observed at the same temperature 
(63.9 ˚C) as the pure PEG 8000. Absence 
of an endothermic peak of drug in SDs has 




The PMs also showed no melting peak 
gliclazide (Fig 3C), though peaks derived 
from gliclazide were observed (Fig 2A). It is 
speculated that gliclazide dissolved in 
molten PEG 8000 during the DSC 
measurement, and that only one 
endothermic peak at 63.4 ˚C, corresponding 
to melting of PEG 8000, was observed. This 
result is in agreement with the report of 
Yamashita et al
23
 who observed in their 
DSC study that the endothermic peak of 
tacrolimus was absent from the thermogram 




The solubility and dissolution rate of 
gliclazide can be enhanced by the use of 
gliclazide - PEG 8000 SDs. The solubilization 
effect of PEG 8000 results in the reduction of 
particle aggregation of the drug, elimination 
of crystallinity, increased wettability and 
dispersibility, and alteration of the surface 
properties of the drug particles, and this is 
probably responsible for the enhanced 
solubility and dissolution rate of gliclazide in 
the SDs and PMs. DSC of gliclazide SDs and 
PMs did not indicate the presence of 
crystalline gliclazide because gliclazide 
dissolved completely below its melting point. 
However, XRD studies indicated the 
presence of 20% crystalline gliclazide in SDs. 
There was no well defined chemical 
interaction between gliclazide and PEG 8000. 
Gliclazide - PEG 8000 SDs provide a 
promising approach to enhance the solubility 
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